Related Experiment Video
Updated: Jun 29, 2025
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
A Predictive Network-Based Immune Checkpoint Blockade Immunotherapeutic Signature Optimizing Patient Selection and
Nan Zhang1, Mei Yang1, Jing-Min Yang1
1Hubei Bioinformatics & Molecular Imaging Key Laboratory, Key Laboratory of Molecular Biophysics of the Ministry of Education, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, 430074, China.
Abstract:
Immune checkpoint blockade (ICB) therapy has brought significant advancements to the field of oncology. However, the diverse responses among patients highlight the need for more accurate predictive tools. In this study, insights are drawn from tumor-immunology pathways, and a novel network-based ICB immunotherapeutic signature, termed ICBnetIS, is constructed. The signature is derived from advanced biological network-based computational strategies involving co-expression networks and molecular interactions networks. The efficacy of ICBnetIS is established through its association with enhanced patient survival and a robust immune response characterized by diverse immune cell infiltration and active anti-tumor immune pathways. The validation process positions ICBnetIS as an effective tool in predicting responses to ICB therapy, analyzing ICB data from a broad collection of over 700 samples from multiple cancer types of more than 15 datasets. It achieves an aggregated prediction AUC of 0.784, which outperforms the other nine renowned immunotherapeutic signatures, indicating the superior predictive capability of ICBnetIS. To sum up, the findings suggest ICBnetIS as a potent tool in predicting ICB therapy responses, offering significant implications for patient selection and treatment optimization in oncology. The study highlights the role of ICBnetIS in advancing personalized treatment strategies, potentially transforming the clinical landscape of ICB therapy.
Insights
A new computational tool, ICBnetIS, accurately predicts patient responses to immune checkpoint blockade (ICB) therapy. This network-based signature improves patient selection for cancer treatment, outperforming existing methods.
Area of Science:
- Oncology
- Immunotherapy
- Computational Biology
Background:
- Immune checkpoint blockade (ICB) therapy has revolutionized cancer treatment.
- Patient responses to ICB vary significantly, necessitating improved predictive biomarkers.
- Understanding tumor-immunology pathways is crucial for optimizing ICB efficacy.
Purpose of the Study:
- To develop a novel network-based immunotherapeutic signature for predicting ICB response.
- To validate the predictive capability of the signature across diverse cancer types.
- To enhance patient stratification for personalized oncology treatment.
Main Methods:
- Construction of a novel signature, ICBnetIS, using biological network-based computational strategies.
- Analysis of co-expression and molecular interaction networks.
- Validation using ICB data from over 700 samples across multiple cancer types and datasets.
Main Results:
- ICBnetIS is associated with enhanced patient survival and robust anti-tumor immune responses.
- The signature achieved a high aggregated prediction AUC of 0.784.
- ICBnetIS outperformed nine other established immunotherapeutic signatures in predictive accuracy.
Conclusions:
- ICBnetIS is a potent and superior tool for predicting response to ICB therapy.
- The signature has significant implications for patient selection and treatment optimization in oncology.
- ICBnetIS advances personalized medicine strategies in cancer care.
